<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953847</url>
  </required_header>
  <id_info>
    <org_study_id>BIO3FDC</org_study_id>
    <nct_id>NCT02953847</nct_id>
  </id_info>
  <brief_title>The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)</brief_title>
  <acronym>BIO3FDC</acronym>
  <official_title>The Bioavailability of Rifampicin in Fixed Dose Combinations (FDCs) Widely Used in South Africa to Treat Drug-susceptible Tuberculosis (TB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing
      FDCs vs a single drug comparator in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the 4- and 2-drug FDCs (for intensive and continuation phases respectively)
      widely used within the South African treatment program will be evaluated in a comparative
      bioavailability study against a single drug rifampicin product registered by the South
      African Medicines Control Council. A three-way, single dose, cross-over study will be
      conducted in 24 healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>AUC to 12 h</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AUC to infinity</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequence 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequence 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequence 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequence 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimactane</intervention_name>
    <description>150 mg capsules, Sandoz MCC registration # A/20.2.3/784</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>sequence 2</arm_group_label>
    <arm_group_label>sequence 3</arm_group_label>
    <arm_group_label>sequence 4</arm_group_label>
    <arm_group_label>sequence 5</arm_group_label>
    <arm_group_label>sequence 6</arm_group_label>
    <other_name>Rifampicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifafour e-275</intervention_name>
    <description>Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>sequence 2</arm_group_label>
    <arm_group_label>sequence 3</arm_group_label>
    <arm_group_label>sequence 4</arm_group_label>
    <arm_group_label>sequence 5</arm_group_label>
    <arm_group_label>sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimactazid 150/75</intervention_name>
    <description>Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.</description>
    <arm_group_label>sequence 1</arm_group_label>
    <arm_group_label>sequence 2</arm_group_label>
    <arm_group_label>sequence 3</arm_group_label>
    <arm_group_label>sequence 4</arm_group_label>
    <arm_group_label>sequence 5</arm_group_label>
    <arm_group_label>sequence 6</arm_group_label>
    <other_name>Rifampicin / Isoniazid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  You need to be between the ages of 18-55 years

          -  Have a Body mass index (BMI) of 19-30 kg/m2

          -  Weigh 45 kg or more

          -  Be a non-smoker

          -  Be found to be in normal health on history and examination

          -  To have normal blood and urine test results

          -  If you are a woman of child-bearing age, you need to be prepared to not have sexual
             intercourse, or use a safe form of contraception, until the end of the study

        Exclusion

          -  You are unable to fully understand and comply with the study procedures, requirements
             and time commitments.

          -  Are currently enrolled in any other study evaluating drugs, biologics or devices

          -  You have TB, or have had TB before

          -  You abuse or have abused drugs or alcohol

          -  You have, or have had, drug allergy, severe asthma, or active or recurrent allergic
             disease

          -  You are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen M McIlleron, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Centre</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7725</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Helen Margaret McIlleron</investigator_full_name>
    <investigator_title>Senior Research Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

